Additionally, no patients included in this study received adjuvant postoperative systemic treatments, such as trastuzumab emtansine in HER2‐positive BC, capecitabine in TNBC, or olaparib in germline BRCA‐mutated TNBC. This evidence concerns the gene ERBB2 and breast cancer.